Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program
Authors' conclusion
Consistent with clinical trial findings, this real-world data analysis showed that semaglutide was well tolerated and that, for a large population, it effectively reduced BMI, body weight and HbA1c, albeit to smaller magnitudes than observed in clinical trials. These findings provide valuable insights into real-world experience and the long-term effectiveness of semaglutide.
Study context
- Population
- Patients with T2D and obesity prescribed semaglutide, All of Us Research Program
- Participants
- 3,364 vs 435
- Exposure
- Injectable vs oral semaglutide
- Injectable semaglutiden = 3,364
- Oral semaglutiden = 435
- Outcome
- Changes from baseline in BMI, weight and HbA1c in semaglutide users
Methodological detailsreal-world utilization data, All of Us Research Program
- Real-world utilization data
- All of Us Research Program
Main finding
As reported in the abstract
Average decrease in body mass index (BMI)
1.54 kg/m²
Average decrease in weight
4.65 kg
Average decrease in HbA1c
0.75%
Observational data: associations, not effects.
Further findings
Time on semaglutide
No end date Injectable semaglutide 20.36% · Oral semaglutide 24.60%
Safety
- Patients reporting newly diagnosed common adverse events
- Approximately only 1.0%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →